CEN Biotech, Inc.
CENBF
$0.0001
$0.000.00%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -50.07% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.07% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -50.07% | -- | -- | -- | -- |
| SG&A Expenses | -32.16% | -94.82% | 39.24% | 105.31% | 45.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.16% | -94.82% | 39.24% | 105.31% | 45.04% |
| Operating Income | 24.59% | 98.16% | 59.43% | -5.14% | -2.01% |
| Income Before Tax | 44.33% | 97.75% | 58.44% | -111.00% | 62.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.33% | 97.75% | 58.44% | -110.81% | 62.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.33% | 97.75% | 58.44% | -110.81% | 62.68% |
| EBIT | 24.59% | 98.16% | 59.43% | -5.14% | -2.01% |
| EBITDA | 43.30% | 98.30% | 80.72% | -6.74% | 4.02% |
| EPS Basic | 58.55% | 98.51% | 73.01% | -105.54% | 78.44% |
| Normalized Basic EPS | 58.95% | 98.53% | 73.05% | 85.56% | 73.90% |
| EPS Diluted | 58.55% | 98.51% | 73.01% | -110.50% | 78.44% |
| Normalized Diluted EPS | 58.95% | 98.53% | 73.05% | 74.03% | 73.90% |
| Average Basic Shares Outstanding | 35.17% | 51.12% | 53.79% | 95.35% | 73.20% |
| Average Diluted Shares Outstanding | 35.17% | 51.12% | 53.79% | 8.87% | 73.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
